Antifungal agents and immunomodulators in systemic mycoses.
The rising incidence of fungal infections and the emergence of several fungi as opportunistic pathogens have reawakened interest in chemotherapeutic and prophylactic agents for mycoses. During the past decades significant advances have been made in the development of novel antifungal agents for treatment of systemic mycoses. This brief review presents an update of the available information on polyenes, imidazoles, triazoles, flucytosine, allylamines, echinocandins, nikkomycins, sordarins and immunomodulators. A reference has also been made to the work in antifungals done or in progress at the Central Drug Research Institute (CDRI), Lucknow. Currently, antifungals represent more than 6% of the total world market for anti-infective agents and with 20% annual expansion they are expected to cross the 15 billion US Dollars in value within a decade.
Khan
Z K
ZK
Medical Mycology Division, Central Drug Research Institute, Lucknow. root@cscdri.ren.nic.in
Jain
P
P
D000935:Antifungal Agents / Q000627:therapeutic use*; D016469:Fungemia / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D009181:Mycoses / Q000188:drug therapy* / Q000276:immunology
D000935:Antifungal Agents; D007155:Immunologic Factors